Treatment of schizophrenia negative symptoms: future prospects
- PMID: 16492797
- PMCID: PMC2632230
- DOI: 10.1093/schbul/sbj055
Treatment of schizophrenia negative symptoms: future prospects
Abstract
New findings from neuroscience, genetics, and experimental psychology have emerged that provide alternative explanations of many negative symptoms. We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments.
References
-
- Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand Suppl. 1995;388:24–30. - PubMed
-
- Lauriello J, Lenroot R, Bustillo J. Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatr Clin North Am. 2003 Mar;26(1):191–211. - PubMed
-
- Kopelowicz A, Liberman R, Mintz J, Zarate R. Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry. 1997;154(3):424–425. - PubMed
-
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51–68. - PubMed
-
- Tollefson G, Bealey C, Tran P, Street J, et al. Olanzapine versus Haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457–474. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical